



Co-creation

Cooperation

Collaboration

**WORKING IN  
PARTNERSHIP  
WITH PATIENTS  
FOR PATIENTS**

# WHO WE ARE?

**Grünenthal is a global leader in pain management and related diseases.**

Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.



## Examples of Grünenthal's sustainable partnerships with patients



**SIP**  
Societal Impact of Pain



**BMP GRANT**  
Patient Centred Innovation

[www.europeanpainfederation.eu/sip/](http://www.europeanpainfederation.eu/sip/)


[www.bmp-grant.eu](http://www.bmp-grant.eu)

# WHY DO WE COLLABORATE WITH PATIENTS?

Having access to appropriate pain treatment is a basic human right<sup>1</sup>.

Grünenthal is committed to embedding patient engagement through each stage in the lifecycle of our medicines and beyond.

We believe that we will achieve this most effectively by working in close partnership with people living with pain, their representatives and carers, and patient organisations in the following areas:



**Together with patients we are seeking for solutions to live a life as normal as possible.**

# HOW DO WE WORK IN PARTNERSHIP WITH PATIENTS AND PATIENT REPRESENTATIVES?

Grünenthal co-operates with patients to support research, healthcare, and education respecting the following principles:

1. Develop and sustain **mutually beneficial relationships** with the patient community
2. Ensure there is **clarity around the roles** for all parties involved
3. Collaborate with patients as **equal partners**
4. Value and **respect the knowledge, skills and independence** of patient representatives
5. Nurture a **culture of mutual respect** based on transparency and high quality, and with regular communication
6. Develop **long term commitment** to collaborate on topics of high importance to patients
7. Use a **co-creation approach** to ensure patient centricity of the clinical development programme, including **priority setting and impact measures** during evaluation
8. **Encourage constructive challenge** in a quest for new ideas, learning and continuous improvement

Grünenthal may provide charitable contributions and donations to support public interest activities. This includes funding, services and the provision of equipment and free products. Grünenthal is committed to publishing information about our collaboration with Patient Organizations (POs) to demonstrate that we interact with them ethically and transparently. <https://www.grunenthal.com/en/responsibility/compliance-ethics-transparency/disclosure-of-transfers-of-value>

We would like to thank Denise Allen (Thurston Arthritis Research Center, US), Francoise Alliot Launois (Association Française de Lutte Anti Rhumatismale, France), Neil Betteridge (independent patient advisor), Natacha Laeremans (ReumaNet, Belgium), Souzi Makri (Cyprus League of People with Rheumatism, Cyprus), Nadia Malliou (Pain Alliance Europe, Belgium), Angie van Bemden (independent patient advisor, US), Cathy van Riel (Liga Reumatológica Espanola, Spain) and the Portuguese League Against Rheumatic Diseases (LPCDR, Portugal) for their contributions and guidance in developing this brochure.

## CONTACT US:

[patientvoice@grunenthal.com](mailto:patientvoice@grunenthal.com)

[www.patient-collaboration.grunenthal.com](http://www.patient-collaboration.grunenthal.com)

